Literature DB >> 19606452

Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients.

Reiji Yoshimura1, Wakako Umene-Nakano, Akihito Suzuki, Nobuhisa Ueda, Kyoko Miyamoto, Atsuko Ikenouchi-Sugita, Hikaru Hori, Koichi Otani, Jun Nakamura.   

Abstract

In the present study, we investigated the relationship between the serotonin transporter gene linked polymorphic regions (5-HTTLPR) or plasma paroxetine levels and clinical response to paroxetine in depressed patients. Sixty patients who met the DSM-IV criteria for major depressive disorder were enrolled in the study. Twenty-two were male and 38 were female, with ages ranging from 25 to 71 (mean +/- SD = 42 +/- 16) years. The clinical improvement of patients was assessed using the Hamilton rating scale for depression (Ham-D) before and every week after paroxetine administration. According to the data reported previously, patients with an at least 50% decrease in their Ham-D score were classified as responders. The results showed that the plasma paroxetine levels at 4 weeks were significantly higher in responders (rapid responders) than in nonresponders. On the other hand, no significant associations were found between the L genotype (L/L, L/S) or S genotype (S/S) and the response rates either at 4 weeks or 8 weeks. These results suggest that patients with higher plasma levels at 4 weeks might respond rapidly to paroxetine treatment, but the final response rate at 8 weeks will be independent of the plasma paroxetine levels and the 5-HTTLPR L/S genotype. 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19606452     DOI: 10.1002/hup.1043

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  10 in total

Review 1.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

Review 2.  Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years.

Authors:  G Voegeli; M L Cléry-Melin; N Ramoz; P Gorwood
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

Review 3.  From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.

Authors:  Chiara Fabbri; Stefano Porcelli; Alessandro Serretti
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

Review 4.  Personalized medicine in psychiatry: problems and promises.

Authors:  Uzoezi Ozomaro; Claes Wahlestedt; Charles B Nemeroff
Journal:  BMC Med       Date:  2013-05-16       Impact factor: 8.775

5.  Pharmacogenomics of antidepressant treatment effects.

Authors:  Julio Licinio; Ma-Li Wong
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

6.  Purine and pyrimidine metabolism: Convergent evidence on chronic antidepressant treatment response in mice and humans.

Authors:  Dong Ik Park; Carine Dournes; Inge Sillaber; Manfred Uhr; John M Asara; Nils C Gassen; Theo Rein; Marcus Ising; Christian Webhofer; Michaela D Filiou; Marianne B Müller; Christoph W Turck
Journal:  Sci Rep       Date:  2016-10-12       Impact factor: 4.379

7.  Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites.

Authors:  Reiji Yoshimura; Taro Kishi; Nakao Iwata
Journal:  Neuropsychiatr Dis Treat       Date:  2019-09-13       Impact factor: 2.570

8.  Association of serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: A preliminary study.

Authors:  Aniruddha Basu; R K Chadda; Mamta Sood; Harpreet Kaur; Ritushree Kukreti
Journal:  Indian J Med Res       Date:  2015-07       Impact factor: 2.375

Review 9.  Systematic review and meta-analysis of serotonin transporter genotype and discontinuation from antidepressant treatment.

Authors:  Andrew A Crawford; Glyn Lewis; Sarah J Lewis; Marcus R Munafò
Journal:  Eur Neuropsychopharmacol       Date:  2012-12-20       Impact factor: 4.600

10.  Paroxetine versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study.

Authors:  Young Sup Woo; Roger S McIntyre; Jung-Bum Kim; Min-Soo Lee; Jae-Min Kim; Hyeon Woo Yim; Tae-Youn Jun
Journal:  Clin Psychopharmacol Neurosci       Date:  2017-11-30       Impact factor: 2.582

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.